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Introduction: Abnormal body temperatures (Tb) are frequently seen in patients with severe sepsis. However, the
relationship between Tb abnormalities and the severity of disease is not clear. This study investigated the impact of
Tb on disease severity and outcomes in patients with severe sepsis.
Methods: We enrolled 624 patients with severe sepsis and grouped them into 6 categories according to their Tb at
the time of enrollment. The temperature categories (≤35.5°C, 35.6–36.5°C, 36.6–37.5°C, 37.6–38.5°C, 38.6–39.5°C,
≥39.6°C) were based on the temperature data of the Acute Physiology and Chronic Health Evaluation II (APACHE II)
scoring. We compared patient characteristics, physiological data, and mortality between groups.
Results: Patients with Tb of ≤36.5°C had significantly worse sequential organ failure assessment (SOFA) scores when
compared with patients with Tb >37.5°C on the day of enrollment. Scores for APACHE II were also higher in
patients with Tb ≤35.5°C when compared with patients with Tb >36.5°C. The 28-day and hospital mortality was
significantly higher in patients with Tb ≤36.5°C. The difference in mortality rate was especially noticeable when
patients with Tb ≤35.5°C were compared with patients who had Tb of >36.5°C. Although mortality did not relate to Tb
ranges of ≥37.6°C as compared to reference range of 36.6–37.5°C, relative risk for 28-day mortality was significantly
greater in patients with 35.6–36.5°C and ≤35.5°C (odds ratio; 2.032, 3.096, respectively). When patients were divided into
groups based on the presence (≤36.5°C, n = 160) or absence (>36.5°C, n = 464) of hypothermia, disseminated intravas-
cular coagulation (DIC) as well as SOFA and APACHE II scores were significantly higher in patients with hypothermia.
Patients with hypothermia had significantly higher 28-day and hospital mortality rates than those without hypothermia
(38.1% vs. 17.9% and 49.4% vs. 22.6%, respectively). The presence of hypothermia was an independent predictor of
28-day mortality, and the differences between patients with and without hypothermia were observed irrespective of
the presence of septic shock.
Conclusions: In patients with severe sepsis, hypothermia (Tb ≤36.5°C) was associated with increased mortality and
organ failure, irrespective of the presence of septic shock.
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Body temperature (Tb) abnormalities are amongst the
most commonly noted symptoms of critically ill patients.
Fever occurs in approximately half of patients admitted to
the ICU and has been associated with adverse outcomes
[1]. Fever is one of the most prominent symptoms of in-
fection [2] and it is part of the host acute-phase response
to infectious as well as non-infectious inflammatory stim-
uli [3]. Fever is also believed to be harmful, especially in
patients with life-threatening illness, because febrile re-
sponses are known to increase the metabolic rate and mi-
nutes ventilation and oxygen consumption, and it can
have adverse effects on neurological outcomes [4-6]. Fever
could also be beneficial because it is believed to reduce
bacterial growth, and a higher Tb is believed to promote
the synthesis of antibodies and cytokines, thereby activat-
ing immune cells and improving survival [7-9]. Several
studies have suggested that suppression of the febrile re-
sponse with antipyretic drugs could worsen patient out-
comes [10,11].
A large epidemiological study that included patients
with and without infection reported that the presence of
fever per se could not be associated with increased ICU
mortality. Nevertheless, fever with Tb ≥39.5°C was associ-
ated with a significant increase in mortality (20.3% versus
12.0% (P <0.001) for patients with Tb ≥39.5°C and <39.5°C,
respectively). These very high fevers could be complicated
with cardiac arrhythmias, tachycardia, increased oxygen
demand, convulsions, and brain damage [1]. A recent
study that used data from Australia, New Zealand, and the
United Kingdom investigated the association between
peak Tb in the first 24 h after admission to ICU and in-
hospital mortality [12]. This study showed that elevated
peak Tb in the first 24 h in the ICU could be associated
with decreased in-hospital mortality in patients with infec-
tion. The lowest mortality risk was among patients with
Tb between 39.0°C and 39.4°C. However, mortality risk
was increased among patients who did not have infection.
Patients with fever in response to non-infective causes
may well experience the harmful effects of fever without
any fever-related benefits, such as protection against vi-
ruses or bacteria.
Hypothermia can be caused by a variety of factors in-
cluding cold exposure, severe infection, endocrine abnor-
malities, and drug overdoses, and hypothermic patients
require immediate medical intervention [13-15]. Although
hypothermia may be an unintended consequence of crit-
ical illness and may be associated with an increased risk of
mortality in patients with sepsis and non-infectious condi-
tions, the influence of hypothermia on the physiological se-
verity and outcome of critically ill patients, particularly
patients with severe sepsis, is not well understood [12,16-22].
Although there are many reports of Tb abnormalities
in patients with sepsis, there is a relative paucity ofinformation on the influences of hyper- or hypothermia
on disease severity and outcomes in patients with severe
sepsis. The aim of present study was to investigate the
association between Tb and disease severity and patient
outcomes in patients with a definitive diagnosis of severe
sepsis.
Materials and methods
This was a prospective study conducted as a part of a mul-
ticenter prospective evaluation of severe sepsis in Japan,
undertaken by the Japanese Association for Acute Medicine
Sepsis Registry (JAAMSR) Study Group [23]. Both the
Japanese Association for Acute Medicine and the Ethics
Committees of the hospitals that participated in this
study approved the study protocol. Data collection was
performed as part of the routine clinical examinations
without any medical intervention. Data management
and statistical analyses were processed anonymously.
Based on these reasons, written informed consent was
waived by both the Japanese Association for Acute
Medicine and the Ethics Committees of the participating
hospitals. The study was registered with the University
Hospital Medical Information Network Clinical Trials
Registry (UMIN-CTR ID: UMIN000008195).
Patients
Between June 1, 2010, and May 31, 2011, we enrolled
624 patients in this study. All of the patients were diag-
nosed with severe sepsis and admitted to one of 15 crit-
ical care centers in the tertiary care hospitals in Japan.
We did not have any exclusion criteria.
Definitions
Sepsis, severe sepsis, septic shock, and systemic inflam-
matory response syndrome (SIRS) were defined accord-
ing to the American College of Chest Physicians/Society
of Critical Care Medicine consensus conference and its
revised version of 2003 [24,25]. The severity of illness
was evaluated according to the acute physiology and
chronic health evaluation (APACHE) II score at the time
of enrollment [26]. Organ dysfunction was assessed ac-
cording to the sequential organ failure assessment
(SOFA) score [27]. Multiple organ dysfunction syndrome
(MODS) was defined as a SOFA score ≥12 [27]. A diag-
nosis of disseminated intravascular coagulation (DIC)
was made on the basis of the scoring system of the
International Society on Thrombosis and Haemostasis
(ISTH) [28]. The change in fibrin/fibrinogen degrad-
ation product (FDP) was used as the fibrin-related
marker for the ISTH criteria. FDP values of <10, ≥10
but <25, and ≥25 mg/L, were defined as no increase,
moderate increase, and strong increase, respectively.
The outcome measure was the 28-day and hospital all-
cause mortality.
Table 1 Baseline characteristics and outcome of the
enrolled patients (n = 624)
Characteristic Value
Age, years 72 (61 – 81)
Gender, male/female 391/233
APACHE II score 23 (17 – 29)
SOFA score 8 (6 – 11)
MODS, n (%) 144 (23.1)















Infective endocarditis 3 (0.5%)
Other 25 (4.0%)
28-day mortality, n (%) 144 (23.1%)
Hospital mortality, n (%) 184 (29.5%)
Values are presented as median (IQR) or number (%). APACHE, acute
physiology and chronic health evaluation; SOFA, sequential organ failure
assessment; MODS, multiple organ dysfunction syndrome.
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Tb recorded within 24 h of a diagnosis of severe sepsis
was used for the APACHE II score and the recorded
temperature was used in this analysis. We recorded the
value measured by the method most preferred by the
American College of Critical Care Medicine and the In-
fectious Diseases Society of America [2]. Although the
method used to measure core Tb was not standardized
and the specific methods used for each individual meas-
urement of core Tb was not recorded in this survey, all
the institutions that participated in this study used
standard methods for determining core Tb. The sites
used for Tb measurement at the institutions were as fol-
lows: urinary bladder, ten institutions; urinary bladder or
rectal, three institutions; rectal, one institution; and
intravascular, one institution. To ascertain the effect of
Tb aberrance on disease severity and outcome, patients
were grouped into one of six categories based on their
core Tb as recorded for the APACHE II scoring. The cat-
egories were ≤35.5°C, 35.6 to 36.5°C, 36.6 to 37.5°C, 37.6
to 38.5°C, 38.6 to 39.5°C, and ≥39.6°C, as previously re-
ported. A core Tb of 35.5°C was taken as the lowest Tb
value because previous studies have reported this
temperature as the threshold of hypothermia with high
mortality [16,29-34]. Although previous studies consid-
ered 35.5°C as the threshold for hypothermia [16,29-32],
we opted to use 36.5°C as the threshold because we
found significant differences in the mortality of patients
with Tb ≤36.5°C compared with those with Tb >36.5°C
based on the results of a temperature categorical ana-
lysis, as shown in Tables 1 and 2. We also compared the
mortality of patients divided into two groups using 36.5°C
as a cutoff value. This analysis demonstrated significant
differences between groups in both the 28-day and hos-
pital mortality (P <0.001). Based on these findings, we
evaluated the effect of hypothermia defined as Tb ≤36.5°C
on not only mortality but also disease severity, which may
affect mortality. For analysis, patients were divided into
two groups, namely, hypothermia (Tb ≤36.5°C, n = 160)
and no-hypothermia (Tb >36.5°C, n = 464).
Assessments
Blood was collected at the time of admission to ICU and
then daily thereafter as part of the routine clinical and
laboratory tests using established standard laboratory
techniques. Platelet counts and coagulation variables ne-
cessary to diagnose DIC were collected and APACHE II,
SOFA, and DIC scores were assessed.
Statistical analysis
Data are expressed as medians and interquartile ranges.
All statistical analyses were performed using SPSS 19.0
for Windows (SPSS, Chicago, IL, USA). Comparisons
between the 2 groups were performed using the Mann-Whitney’s U test, and categorical variables were summa-
rized using proportions and compared between groups
using either the Pearson’s chi-square or Fisher’s exact
test, where appropriate. Kruskal-Wallis one-way analysis
of variance and multiple chi-square tests were used for
comparisons between multiple groups, and P-values
were adjusted with the Bonferroni correction for mul-
tiple testing.
Odds ratios (OR) are reported relative to a reference
range of Tb, as previously reported [33]. We defined the
reference range here as the Tb category of 36.6 to 37.5°C.
Additionally, survival curves were derived by the Kaplan-
Meier method and compared by the log-rank test for each
range. We used a multivariate logistic model to assess the
relationships between 28-day mortality and independent
variables in patients with severe sepsis. Outcome (dead, 1;
survived, 0) was used as the criterion variable, and age,
gender (male or female), admission category of underlying
medical condition (medical or other cause), SOFA score,
APACHE II score, positive blood culture (yes or no), the
Table 2 Body temperature and severity of coagulation abnormality/organ failure scores
Body temperature, °C








≥39.6 (n = 64)
Age, years 76 (65 to 82)de 78 (62.5 to 83.5)de 75 (66 to 84)de 72 (61 to 82)de 67 (58 to 76) 65 (45.25 to 78.75)
Septic shock, n (%) 62 (62.6%)bcde 33 (54.1%) 46 (41.1%) 63 (40.6%) 54 (40.6%) 24 (37.5%)
SIRS criteria 4 (3 to 4)abc 3 (2 to 4)bde 3 (2 to 3)cde 3 (3 to 4)de 4 (3 to 4) 4 (3 to 4)
DIC score 5 (2 to 6)c 4 (2 to 6) 4 (2 to 5) 3 (2 to 5) 3 (2 to 5) 3 (2 to 5)
DIC ≥5, n (%) 28 (28.3%)cde 15 (24.6%)c 22 (19.6%) 20 (12.9%) 21 (15.8%) 7 (10.9%)
SOFA score 10 (7 to 12)cde 10 (7 to 13)cde 8 (5 to 11) 8 (5 to 11) 7 (5 to 10.75) 7 (6 to 10)
MODS, n (%) 35 (35.4%)cde 23 (37.8%)cde 27 (24.1%) 32 (20.6%) 23 (17.3%) 10 (15.6%)
APACHE II 28 (23 to 33)bcde 24 (20 to 29) 21 (16.25 to 27) 21 (16 to 27) 22 (17 to 26) 22 (17.25 to 30)
Outcome
28-day mortality, n (%) 40 (40.4%)bcde 21 (34.4%)cde 23 (20.5%) 28 (18.1%) 21 (15.8%) 11 (17.2%)
Hospital mortality, n (%) 52 (52.5%)bcde 27 (44.3%)bcde 27 (24.1%) 39 (25.2%) 26 (19.5%) 13 (20.3%)
SIRS, systemic inflammatory response syndrome; DIC, disseminated intravascular coagulation; SOFA, sequential organ failure assessment; MODS, multiple organ
dysfunction syndrome; APACHE, acute physiology and chronic health evaluation. aP <0.0033 (after Bonferroni correction) versus 35.6 to 36.5°C; bversus 36.6 to
37.5°C; cversus 37.6 to 38.5°C; dversus 38.6 to 39.5°C; eversus ≥39.6°C.








≤35.5 40.4% 3.096 1.611, 5.947 0.001
35.6 to 36.5 34.4% 2.032 1.009, 4.088 0.047
36.6 to 37.5 20.5% 1.000 (reference)
37.6 to 8.5 18.1% 0.853 0.461, 1.577 0.621
38.6 to 39.5 15.8% 0.726 0.377, 1.395 0.404
≥39.6 17.2% 0.803 0.363, 1.778 0.693
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(Tb ≤36.5°C or >36.5°C) were used as explanatory vari-
ables. Results are reported as OR, P-values, and 95%
CI. Differences with a P-value <0.05 were considered to
be statistically significant. Furthermore, P <0.0033 (after
Bonferroni correction) was used for comparisons be-
tween groups in multiple testing (Table 2).
Results
Baseline characteristics and patient outcome
During the 1-year study period, a total of 14,417 patients
were admitted to the 15 critical care centers, and 624
(4.3%) of these patients were diagnosed with severe sep-
sis and enrolled in this study. The characteristics at en-
rollment and outcomes of patients are shown in Table 1.
The mean age was 69 years, and the mean initial APA-
CHE II score and SOFA scores were 23.4 and 8.6, re-
spectively. The major sites of infection were pulmonary,
intra-abdominal, urinary, and skin/soft tissue. More than
half of the patients had dysfunction of three or more
organ systems. The 28-day mortality was 23.1% and the
overall hospital mortality was 29.5%. Sepsis-related hos-
pital mortality was 25.6% (160/624 patients).
Relationships between body temperature and severity
scores
Patients with Tb >38.5°C were significantly younger than
patients with Tb ≤38.5°C. The prevalence of septic shock
was significantly higher among patients with Tb ≤35.5°C
when compared with the incidence of septic shock
among patients in the other Tb categories (Table 2). MODS
and SOFA on the day of enrollment were significantly
higher in patients with Tb 35.6 to 36.5°C and ≤35.5°C
when compared with patients who had Tb >37.5°C. TheAPACHEII scores in patients with Tb ≤35.5°C were sig-
nificantly higher when compared with patients who had
Tb of >36.5°C.
For mortality rates, patients who had Tb ≤36.5°C had
significantly higher 28-day and hospital mortality rates
when compared with patients who had Tb >36.5°C. The
mortality rate among patients who had Tb ≤35.5°C was
especially high at 40.4% and 52.5% for 28-day and hos-
pital mortality rates, respectively. The lowest 28-day and
hospital mortality were noted in patients with Tb be-
tween 38.6 and 39.5°C (15.8% and 19.5%, for 28-day and
hospital mortality, respectively) (Table 2).
Body temperature and mortality
Table 3 shows 28-day mortality and OR for each Tb (taken
on day 1) relative to the reference range of 36.6 to 37.5°C.
We found no relationships between mortality and Tb in
patients in the following categories: 37.6 to 38.5°C, 38.6 to
39.5°C, and ≥39.6°C. The relationship between mortality
and Tb was significant in patients in the Tb categories
of 35.6 to 36.5°C (OR 2.032, P = 0.047) and ≤35.5°C
(OR 3.096, P = 0.001). Kaplan-Meier estimates for the
probability of survival at 28 days were lower in patients
Table 4 Characteristics, physiology on day 1 and
outcome in hypothermic (body temperature ≤36.5°C) and






Age, years 76 (64.25 to 83) 71 (60 to 80) 0.001
Septic shock 59.4% (n = 95) 40.3% (n = 187) <0.001
DIC score 4 (2 to 6) 3 (2 to 5) 0.009
SOFA score 10 (7 to 13) 8 (5 to 11) <0.001
APACHE II score 26 (21 to 32) 21 (16.25 to 27) <0.001
Outcome
28-day mortality 38.1% (n = 61) 17.9% (n = 83) <0.001
Hospital mortality 49.4% (n = 79) 22.6% (n = 105) <0.001
Results are presented as median (IQR) or % (number). DIC, disseminated
intravascular coagulation; SOFA, sequential organ failure assessment; APACHE,
acute physiology and chronic health evaluation.
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pared to patients who had Tb ≥36.6°C (Figure 1).
Severity scores and outcome in hypothermic and non-
hypothermic patients
After analyzing the data for the different Tb categories,
we defined 36.5°C as the threshold temperature for
hypothermia and compared variables and outcomes be-
tween patients with hypothermia (≤36.5°C, n = 160) and
those without hypothermia (>36.5°C, n = 464).
The incidence of septic shock was significantly higher
in patients with hypothermia compared to patients with-
out hypothermia. DIC, SOFA, and APACHE II scores
and the incidence of MODS were significantly increased
among hypothermic patients (Table 4). In hypothermic
patients, 28-day and hospital mortality were higher
(more than double) than the mortality rates of patients
without hypothermia (38.1% versus 17.9%, 49.4% versus
22.6%, for 28-day and for hospital mortality, respectively)
(Table 4).
Comparisons of severity scores and outcome between
hypothermic and non-hypothermic patients with and
without septic shock
The incidence of septic shock was significantly higher in
patients with hypothermia. We separately evaluated theFigure 1 Body temperature within 24 h of ICU admission and
survival of patients with severe sepsis. This figure depicts the
Kaplan-Meier estimates for the probability of survival, which at 28
days was lower in patients with body temperature of ≤35.5°C and
35.6 to 36.5°C, as compared to patients with body temperatures of
36.6 to 37.5°C, 37.6 to 38.5°C, 38.6 to 39.5°C, and ≥39.6°C (P <0.001).
Body temperature was recorded as the highest score on the acute
physiology and chronic health evaluation (APACHE) II scoring system
and as the farthest value from 36.5 to 37.0°C within 24 h from the
time of enrollment, which was divided into categorical variables with
1°C increments. Thus, body temperature was analyzed in six range
categories: ≤35.5°C, 35.6 to 36.5°C, 36.6 to 37.5°C, 37.6 to 38.5°C, 38.6
to 39.5°C, and ≥39.6°C.influence of hypothermia on variables and outcomes in
patients with and without septic shock, because mortal-
ity and severity scores in patients with septic shock were
significantly higher when compared with other patients
[23]. Patients with septic shock had higher DIC, SOFA,
and APACHE II scores if they were hypothermic at the
time of diagnosis. In these hypothermic patients, both
28-day and hospital mortality were nearly twice those of
patients with septic shock and no hypothermia (Table 5).
In patients without septic shock, hypothermic patients
had a significantly higher incidence of MODS and they
also had significantly higher SOFA and APACHE II
scores when compared with patients who did not have
hypothermia. Although the 28-day mortality was not
significantly different between hypothermic and non-
hypothermic patients, hospital mortality in hypothermic
patients was nearly twice that of non-hypothermic pa-
tients (30.8% versus 17.0%) (Table 6). The 28-day and
hospital mortality rates in hypothermic patients withoutTable 5 Characteristics, physiology on day 1, and
outcome in hypothermic (body temperature ≤36.5°C) and






Age, years 75 (62 to 83) 72 (61 to 79) 0.069
DIC score 4.0 (2.0 to 5.0) 3.0 (2.0 to 5.0) 0.047
SOFA score 11.0 (9.0 to 13.0) 10.0 (8.0 to 13.0) 0.039
APACHE II score 29.0 (23.0 to 35.0) 25.0 (19.0 to 31.0) 0.001
Outcome
28-day mortality 49.5% (n = 47) 24.6% (n = 46) < 0.001
Hospital mortality 62.1% (n = 59) 31.0% (n = 58) < 0.001
Results are presented as median (IQR) or % (number). DIC, disseminated
intravascular coagulation; SOFA, sequential organ failure assessment; APACHE,
acute physiology and chronic health evaluation.
Table 6 Characteristics, physiology on day 1, and
outcome in hypothermic (body temperature ≤36.5°C) and






Age, years 78 (70 to 82.5) 71 (58 to 81) 0.004
DIC score 3 (2 to 5) 3 (2 to 5) 0.133
SOFA score 7.5 (5 to 11) 6 (4 to 8) 0.004
APACHEII score 24 (18 to 27) 19 (15 to 24) <0.001
Outcome
28-day mortality 21.5% (n = 14) 13.4% (n = 37) 0.096
Hospital mortality 30.8% (n = 20) 17.0% (n = 47) 0.012
DIC, disseminated intravascular coagulation; SOFA, sequential organ failure
assessment; APACHE, acute physiology and chronic health evaluation. Results
are presented as median (IQR) or % (number).
Table 7 Results of multivariate logistic regression
analysis for the prediction of 28-day mortality
Factors Odds ratio P value 95% CI
Severe sepsis (n = 602)
Age 1.026 0.001 1.010–1.042




SOFA score 1.111 0.002 1.041–1.186
APACHE II score 1.062 0.000 1.029–1.095
Positive blood culture 1.471 0.073 0.965–2.242




Severe sepsis with septic shock (n = 273)
Age 1.036 0.001 1.014–1.059




SOFA score 1.078 0.119 0.981–1.186
APACHE II score 1.050 0.019 1.008–1.094
Positive blood culture 1.761 0.052 0.996–3.114




CI, confidence interval; SOFA, Sequential Organ Failure Assessment; APACHE, Acute
Physiology and Chronic Health Evaluation; Comorbidity, at least one comorbidity.
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shock were both double those in patients who were non-
hypothermic and did not have septic shock. In addition, the
28-day and hospital mortality rates in hypothermic patients
with septic shock were almost four times higher than those
in non-hypothermic patients without septic shock.
Table 7 shows that hypothermia, defined as a core Tb
of ≤36.5°C, was an independent predictor of 28-day mor-
tality in patients with severe sepsis, especially in the
presence of septic shock.
Discussion
The results of this study clearly indicate that the mortal-
ity rate amongst patients with severe sepsis is signifi-
cantly higher among those who have a Tb of ≤36.5°C
compared to those who have a Tb of >36.5°C measured
within 24 h of diagnosis. In this study, the mortality rate
was more than two times higher among patients with se-
vere sepsis who were hypothermic compared to patients
with severe sepsis who had no hypothermia. Further-
more, the higher mortality rate was associated with a de-
terioration of organ function and DIC. The effect of
hypothermia on mortality rate was consistently observed
in patients with and without septic shock.
In our study, elevated Tb was not associated with an
increase in disease severity or risk of mortality. More-
over, elevated Tb was not associated with a progressive
increase in disease severity or mortality when compared
with the reference Tb range of 36.6 to 37.5°C. Our re-
sults suggest that higher Tb is not harmful in patients
with severe sepsis. Studies investigating the effect of
fever control by means of antipyretic treatment or exter-
nal cooling and the risk of mortality have reported con-
trasting results, and it is clear that the role of fever and
its control in patients with severe sepsis still needs to be
elucidated [34,35].
It has been suggested that hypothermia is associated
with an increased risk of mortality in critically illpatients [12,33]. Moreover, the effect of hypothermia on
increased mortality has been shown in patients with and
without infection [12,17,18]. In the Methylprednisolone
Severe Sepsis Study database, the Veterans Administra-
tion Systemic Sepsis Cooperative Study of Glucocortic-
oid Therapy, and the Ibuprofen Sepsis Study, the
threshold Tb for hypothermia was set at 35.5°C and pa-
tients with severe sepsis were included. The incidence of
hypothermia (<35.5°C), 28- or 30-day mortality in patients
with hypothermia versus patients without hypothermia in
these studies were 9%, 62% versus 26%; 10%, 57% versus
28%; and 9.6%, 70% versus 35%, respectively. The NORA-
SEPT II study included only patients with septic shock
and the incidence of hypothermia among these patients
was 21%. The mortality in patients with hypothermia and
in those without hypothermia was 59% and 34%, respect-
ively. In the present study, the incidence of mortality
among patients with Tb ≤35.5°C was 15.9% (99/624 pa-
tients), and the 28-day and hospital mortality rates were
also significantly higher when compared with other pa-
tients (Tb >35.5°C; 40.4% versus 19.8%, 52.5% versus
25.1%, for 28-day and hospital mortality, respectively).
Although the underlying mechanism of sepsis-related
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with previous studies [16,29-32].
We defined 36.5°C as the threshold of hypothermia
based on the results of our evaluation of the outcomes
for the different Tb categories. We also generated the re-
ceiver operating characteristic curves using Tb on the
day of enrollment for the 28-day and hospital mortality
evaluation. The analysis revealed that the cutoff values
for predicting the 28-day and hospital mortality were
36.9°C and 36.3°C, respectively, for maximizing both
sensitivity and specificity (data not shown), and these
suggest a Tb of 36.5°C as an acceptable cutoff value to
define hypothermia in this study.
Although the impact of hypothermia, defined as a
threshold temperature of 35.5°C, on mortality has been
demonstrated in previous studies [16,29-32], the effect of
hypothermia on disease severity has not been fully evalu-
ated. Therefore, we evaluated the effects of Tb ≤36.5°C on
both mortality and disease severity by comparing patients
with and without hypothermia. The incidence of organ
failure, DIC and outcomes were significantly different
in patients with Tb of ≤36.5°C compared to those with
Tb of >36.5°C, and there was no significant difference
between patients who had Tb of ≤35.5°C compared to
those with a Tb of >35.5°C. Therefore, 36.5°C was consid-
ered the threshold for hypothermia in patients with severe
sepsis, irrespective of the presence of septic shock.
It is important to note that the inclusion of Tb abnor-
malities as a measure of the severity of illness varies be-
tween different scoring systems. APACHE II assigns
points for patients with either high or low Tb, SAPS II
only assigns points for high Tb, and SAPS III only as-
signs points for low Tb [26,36,37]. Although it is widely
accepted that fever has an adverse effect on patients with
neurologic injury [38], little is known about the impact
of temperature abnormalities on the outcome of other
ICU patients, especially patients with sepsis [1,18]. The
results of this study add valuable knowledge with regard
to the influence of Tb abnormalities on the outcome of
patients with severe sepsis. From our results, it is clear
that hypothermia has a greater impact on organ dysfunc-
tion and outcomes. Thus far, the mechanism underlying
the harmful effects of hypothermia is not yet known, but
it is evident that hypothermia is more important than el-
evated temperature for the severity of illness scores in
patients with severe sepsis.
Limitations
There are some limitations to our study. Tb was re-
corded within 24 h of a diagnosis of severe sepsis as the
highest core Tb value of the APACHE II score. However,
we did not standardize the method by which core Tb
was measured, and we did not attempt to differentiate
between patients who had an elevated Tb as a result ofhyperthermia syndrome or because of fever. Although
some patients might have been categorized differently if
we employed a systematic protocol for measuring Tb,
our recorded core Tb data were not merely arbitrary
values obtained within the 24-h period after a diagnosis
of severe sepsis, but these measurements were assessed
objectively. In addition, the outcome and influence of
treatment may vary significantly on that basis.
We did not specifically control for therapeutic modalities
that may have influenced Tb, such as antipyretic drugs or
active external temperature control strategies. Although it
is widely accepted that temperature control improves
outcome in patients with neurologic injury, the effect of
acetaminophen, ibuprofen, or external control on the out-
come of other critically ill patients is not well understood.
Conclusions
Tb of patients with severe sepsis, as measured at the time
of diagnosis, significantly affected patient outcome. In our
study, hypothermia (≤36.5°C) was associated with a sig-
nificantly higher risk of mortality. The risk of mortality
was almost double among hypothermic patients compared
to patients without hypothermia. Hypothermia was also
associated with a significant physiological decline in these
patients, irrespective of whether they experienced septic
shock or not. Elevated Tb was not associated with an in-
creased disease severity and risk of mortality.
Key messages
 In patients with severe sepsis, the impact of elevated
body temperature and hypothermia on mortality
and severity of physiologic decline is different.
 Hypothermia, defined as body temperature of ≤36.5°C,
is significantly associated with an increased mortality
risk of more than double that of non-hypothermic
patients; moreover, it is associated with a physio-
logical decline in severe sepsis, irrespective of the
presence of septic shock.
 Elevated body temperature was not associated with
increased disease severity or risk of mortality.
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